Category Archives: Healthcare

Acasti Pharma (ACST) Received its Third Buy in a Row

After Echelon Wealth Partners and H.C. Wainwright gave Acasti Pharma (NASDAQ: ACST) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Leland Gershell maintained a Buy rating on Acasti Pharma today and set a

H.C. Wainwright Sticks to Its Buy Rating for Fennec Pharmaceuticals (FENC)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Fennec Pharmaceuticals (FENC – Research Report), with a price target of $17.00. The company’s shares closed last Monday at $7.82, close to its 52-week high

Analysts Offer Insights on Healthcare Companies: Fortress Biotech (NASDAQ: FBIO) and Baudax Bio (NASDAQ: BXRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fortress Biotech (FBIO – Research Report) and Baudax Bio (BXRX – Research Report) with bullish sentiments. Fortress Biotech (FBIO) B.Riley FBR analyst

Analysts Offer Insights on Healthcare Companies: Selecta Biosciences (NASDAQ: SELB), ImmunoGen (NASDAQ: IMGN) and Crispr Therapeutics AG (NASDAQ: CRSP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Selecta Biosciences (SELB – Research Report), ImmunoGen (IMGN – Research Report) and Crispr Therapeutics AG (CRSP – Research Report) with bullish sentiments.

Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (NASDAQ: ATRA) and ESSA Pharma (NASDAQ: EPIX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atara Biotherapeutics (ATRA – Research Report) and ESSA Pharma (EPIX – Research Report) with bullish sentiments. Atara Biotherapeutics (ATRA) Canaccord Genuity analyst

Oppenheimer Remains a Buy on Moderna (MRNA)

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Moderna (MRNA – Research Report) yesterday and set a price target of $31.00. The company’s shares closed last Monday at $19.00. According to TipRanks.com, Singh is a 3-star analyst with an